Companies › Marengo Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STAR0602 Selective TCR-targeting bifunctional antibody-fusion molecule | TCRA, TCRB | Phase 1 | Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid Tumors | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06827613 | STAR0602 | Phase 1 | Triple Negative Locally Advanced Non-resectable Breast Cancer | Oncology | Jan 2027 |
| NCT05592626 | STAR0602 | Phase 1 | Advanced Solid Tumors | Oncology | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.